Abstract
Multiple myeloma is considered a hypercoagulable state due to several mechanisms such as the increased IL-6 and immunoglobulins production, the defective fibrinolytic mechanism, and the acquired resistance to activated protein C that are involved in the pathogenesis and clinical futures of the disease. We describe a case of a female patient who presented to the hospital with pulmonary embolism as the first manifestation of the hypercoagulability of multiple myeloma.
Highlights
Venous thromboembolic disease has been well established as a major complication of myeloma therapy [1,2,3]
Multiple myeloma patients have decreased fibrinolytic activity because of increased PAI-1 activity, which is positively related to elevated IL-6 levels [11]
Apart from having an increased risk of pulmonary embolism due to immunomodifying agents that are included in multiple myeloma therapy, patients with newly diagnosed multiple myeloma, that is prior to having received therapy, seem to be at increased risk for venous thromboembolic disease and pulmonary embolism [12]
Summary
Internal Medicine Department, Evangelismos General Hospital, 45-47 Ipsilantou Street, 10676 Athens, Greece. Multiple myeloma is considered a hypercoagulable state due to several mechanisms such as the increased IL-6 and immunoglobulins production, the defective fibrinolytic mechanism, and the acquired resistance to activated protein C that are involved in the pathogenesis and clinical futures of the disease. We describe a case of a female patient who presented to the hospital with pulmonary embolism as the first manifestation of the hypercoagulability of multiple myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have